Human Accell siRNA Library - Druggable Genome

Accell siRNA permits RNAi screening in difficult-to-transfect cells with no transfection reagent, virus, or electroporation.


An arrayed siRNA collection targeting human genes that are potential therapeutic targets

The Accell Druggable Genome library contains the genes that are considered potential targets for therapeutics, and have been assembled from multiple curated databases (see References tab). This extensive library is delivered as eight distinct subset siRNA libraries in the 96-well format. In the 384-well format the first seven subsets are plated continuously to reduce partial plates.

Accell siRNA achieves what no other RNAi product can claim: delivery into difficult-to-transfect cells without transfection reagents, virus, or electroporation. Researchers around the world are achieving targeted gene silencing in cells that had previously been beyond the reach of conventional RNAi products due to toxicity caused by transfection reagents or undesirable viral responses.

Highlights

  • Accell siRNA enters cells without the need for transfection reagents, virus (or viral vectors), or instruments
  • Proven performance in neuronal, immunological, primary, and other difficult-to-transfect cell types
  • Extended-duration knockdown with optimized continuous application
  • Available as SMARTpool siRNA reagents or a Set of 4 siRNAs in 96 or 384-well plates

Eight subsets make up the Accell Human Druggable Genome siRNA Library

  • GPCR
  • Protein Kinases
  • Ion Channels
  • Phosphatases
  • Proteases
  • Ubiquitin Enzymes
  • Transcription Factors
  • Drug Targets
 

Experimental Considerations

  • Accell siRNA works at a higher concentration than conventional siRNA; recommended 1 µM working concentration, but should be optimized.
  • Delivery may be inhibited by the presence of BSA in serum. Optimization studies with serum-free media formulations (Accell Delivery Media) or < 2.5% serum in standard media is recommended
  • Full-serum media can be added back after 48 hours of incubation. Optimal mRNA silencing is typically achieved by 72 hours or up to 96 hours for protein knockdown

 

  
HazardousNo
Shelf Life12 Months
Shipping ConditionAmbient
Stability at Recommended Storage ConditionsAt least 12 months
Storage Condition-20 C
The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

(1) Combine Accell siRNA with Accell delivery media (or other low- or no-serum media). (2) Add Accell delivery mix directly to cells, and incubate for 72 hours.


Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Internal validation and peer-reviewed publications report numerous successes with difficult-to-transfect cell types. See the References tab for a list of publications.


References

  1. The Drug-Gene Interaction Database http://dgidb.org/
  2. Pharos: Illuminating the Druggable Genome https://pharos.nih.gov/

  3. IUPHAR/BPS  http://www.guidetopharmacology.org/lists.jsp
  4. B.D. Parsons, A. Schindler, D.H. Evans, E. Foley, A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay. PLoS One. 4(12), e8471 (2009).
  5. M. Jiang, R. Instrell, B. Saunders, H. Berven, M. Howell, Tales from an academic RNAi screening facility; FAQs. Brief Funct. Genomics. 10(4), 227-237 (2011). [doi: 10.1093/bfgp/elr016]

Citations

  1. Click to view a more comprehensive list of Accell siRNA citations.
  2. S. Suzuki et al.Differential Roles of Epac in Regulating Cell Death in Neuronal and Myocardial CellsJ. Biol. Chem285, 24248-24259 (July 2010). [primary mouse cortical neurons (E15-17)]
  3. U. Dreses-Werringloer et al.A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Ab Levels, and Alzheimer’s Disease Risk. Cell. 133, 1149-1161 (27 June 2008). [SHSY-5Y; human neuroblastoma]
  4. S. Byas et al.Human Embryonic Stem Cells Maintain Pluripotency after E-Cadherin Expression Knockdown. FASEB J. 24, lb172 (Apr 2010). [H9 stem cell lines]
  5. V. Saini et al.CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin. J. Biol. Chem.  285, 15566-15576 (May 2010). [THP-1 monocytes]
  6. D. Smirnov et al.Genetic Analysis of Radiation-induced Changes in Human Gene Expression. Nature. 459, 10.1038/nature07940 (28 May 2009). [immortalized B cells]